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Objective: A familial history of ovarian cancer/breast cancer is considered a signiﬁcant prognostic factor
for ovarian cancer. We investigated hereditary factors by examining the incidence of synchronous ma-
lignancy in patients with endometrial cancer, and assessed the prognostic role of heredity in endometrial
cancer.
Methods: We retrospectively evaluated patients with endometrial cancer who underwent surgery from
January 2001 to April 2011. A hereditary background in this study was deﬁned as double primary cancer,
that is, endometrial cancer accompanied by colon, ovarian, or breast cancer suggestive of Lynch syn-
drome, hereditary breast ovarian cancer syndrome, or Cowden syndrome, respectively.
Results: Among 282 patients with endometrial cancer in the study population, 20 patients (7.1%) had a
hereditary predisposition: 10 patients (3.5%) had ovarian cancer, six patients (2.1%) had breast cancer,
and four patients (1.4%) had colon cancer. Age and lower uterine segment involvement were not sta-
tistically different between the hereditary and nonhereditary groups. The majority of the women in the
hereditary group presented with Stage I cancer; however, there were no signiﬁcant differences in Stage I
cancer between the hereditary group and the sporadic endometrial cancer group (85% and 77%,
respectively, p ¼ 0.561). The median follow-up period was 60 months. A 5-year overall survival rate was
not different between the two groups (95% and 95%, respectively, p ¼ 0.659). Among a subgroup of
patients with Stage I endometrial cancer, the 5-year overall survival rate was lower in the endometrial
cancer with a hereditary predisposition group compared with the sporadic endometrial cancer group
(94% and 98%, respectively, p ¼ 0.027).
Conclusion: Seven percent of the women with endometrial cancer in our study had other malignancies
such as ovarian, colon, or breast cancer synchronously. Among a subgroup of patients with Stage I cancer
in the endometrial cancer with a hereditary predisposition group, the 5-year overall survival rate was
signiﬁcantly lower (94%). This ﬁnding should be conﬁrmed in a larger population.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
The incidence of endometrial cancer has been increasing over
the past decade in Korea [1e3]. Among the many risk factors for, Research Institute and Hos-
-gu, Goyang-si, Gyeonggi-do,
bstetrics & Gynecology. Publishedendometrial cancer, including obesity, diabetes, late menopause,
unopposed estrogen therapy, and nulliparity [4], inherited factors
have also been suggested as important risk factors [5].
The occurrence of synchronous cancers is relatively uncommon,
but it is important to detect them in clinical practice because a
diagnosis of synchronous malignancy in the later stages affects
clinical management and prognosis. In particular, double primary
cancer with endometrial cancer is strongly associated with he-
reditary factors; for example, colon cancer and endometrial cancer,
suggestive of Lynch syndrome [5], ovarian cancer and endometrialby Elsevier Taiwan LLC. All rights reserved.
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ovarian cancer syndrome [6], and breast cancer and endometrial
cancer, suggestive of Cowden syndrome [7].
A familial history of ovarian cancer/breast cancer is considered a
strong prognostic factor for ovarian cancer, and this might be
explained by BRCAness [8]. However, double primary cancer with
endometrial cancer has not been well studied previously. There-
fore, we investigated the prognostic role of heredity in endometrial
cancer, a potentially autosomal dominant disease.
Materials and methods
A total of 282 patients were diagnosed with endometrial cancer
by pathologic examination at the Department of Uterine Cancer at
the National Cancer Center Korea between January 2000 and April
2011. This retrospective study was approved by the Institutional
Review Board of the National Cancer Center (NCCNCS-12-597). A
hereditary background in this study was deﬁned as the existence of
a primary cancer concurrent with endometrial cancer, that is, colon
cancer and endometrial cancer, suggestive of Lynch syndrome,
ovarian cancer and endometrial cancer, suggestive of Lynch syn-
drome and/or hereditary breast ovarian cancer syndrome, and
breast cancer and endometrial cancer, suggestive of Cowden syn-
drome. The clinicopathological factors analyzed were age at the
time of diagnosis, body mass index (BMI), parity, menstrual history,
history of diabetes, tumor histology, tumor grade, the International
Federation of Gynecology and Obstetrics stage, and involvement of
the lower uterine segment.
In the cases of synchronous cancers of the endometrium and
ovary, all surgical specimens were examined by gynecologic pa-
thologists, according to the criteria described by Scully et al [9]. The
pathological criteria for synchronous primary cancers of the
endometrium and ovary were as follows: (1) histological dissimi-
larity of tumors; (2) no or only superﬁcial myometrial invasion of
endometrial tumor; (3) no vascular space invasion of endometrial
tumor; (4) atypical endometrial hyperplasia additionally present;
(5) absence of other evidence of spread of endometrial tumor; (6)
unilateral ovarian tumor (80e90% of cases); (7) ovarian tumors
located mainly in the parenchyma; (8) no vascular space invasion,
surface implants, or predominant hilar location in the ovary; (9)
absence of other evidence of the spread of ovarian tumor; and (10)
presence of ovarian endometriosis [9]. In the cases of synchronous
cancers of the endometrium and breast or endometrium and colon,
the records of the patients with a preexisting diagnosis of breast or
colon cancer were examined to determine whether the endome-
trial cancer was a concurrent disease or a metastatic one. It has
been reported that the risk of tamoxifen-related endometrial can-
cer increases proportionally with the duration of tamoxifen use
irrespective of menopausal status [10]. In the current study,
endometrial cancer patients who used tamoxifen for 5 or more
years (odds ratio, 2.4; 95% conﬁdence interval, 1.8e3.0) were
excluded [10].
All oncological treatments were performed in accordance with
institutional guidelines, which were based on the National
Comprehensive Cancer Network (NCCN) guideline and the Health
Insurance Review and Assessment Service (HIRA) in Korea. All pa-
tients underwent total hysterectomy and pelvic lymph node
dissection, with or without para-aortic lymph node dissection.
Adjuvant pelvic radiation after complete surgical staging was per-
formed in patients with potential adverse risk factors such as age,
grade, lymphovascular invasion, tumor size, lower uterine
involvement, and outer-third myometrial invasion [11e13].
Adjuvant chemotherapy was performed in patients with Stage
IVb disease or concurrent ovarian cancer. However, the endometrial
patients with concurrent ovarian cancer, which was stage Ia or Iband Grade 1 tumor, were not performed adjuvant chemotherapy
based on the NCCN guideline. We reviewed the medical records,
such as the stages for each cancer, tumor markers, and imaging
studies, to exclude the possibility of recurrence from colon or breast
cancer. In this study, we excluded all patients who had uncertain
recurrence from endometrial or colon/breast cancer.
Chi-square test and t tests were used to evaluate differences in
patient and tumor characteristics between the sporadic and he-
reditary endometrial cancer groups including age at diagnosis,
menopause, BMI, parity, diabetes, stage, tumor grade, endometrial
cancer histology, and lower uterine segment involvement. Endo-
metrial cancer-speciﬁc survival was used for analysis.
KaplaneMeier survival analyses were generated and compared by
the log-rank test. A p value <0.05 was taken to be signiﬁcant. All the
analyses were performed using STATA 11.0 (STATACORP, College
Station, TX, USA) and SPSS 21.0 (IBM-SPSS Inc., Chicago, IL, USA).
Results
The clinicopathological characteristics of endometrial cancer
according tohereditarycomponents arepresented inTable 1.Among
282 patients with endometrial cancer in the study population, 20
patients (7.1%) had a hereditary predisposition: 10 patients (3.5%)
had ovarian cancer, six patients (2.1%) had breast cancer, and four
patients (1.4%) had colon cancer. The mean age of the total endo-
metrial cancer patients at onset was 53.2± 12.1 years (range, 23e81
years). The mean age at diagnosis of endometrial cancer for the
hereditary predisposition was not statistically different compared
with the mean age at diagnosis for the sporadic endometrial cancer
group (55 years and 53 years, respectively, p ¼ 0.791). The per-
centage of patients diagnosed at an age younger than 50 years in the
hereditary endometrial cancer group was 40%, and there were no
signiﬁcant differences in this percentage between the sporadic
endometrial cancer group and the endometrial cancer with a he-
reditary predisposition group (p¼ 0.428). The BMI and incidence of
diabetes were not signiﬁcantly different between the sporadic
endometrial cancer group and the endometrial cancer with a he-
reditarypredispositiongroup (p¼0.434andp¼0.149, respectively).
As shown in Table 2, both cancers were detected simultaneously
in the majority of the synchronous cases (55%). All ovarian cancers
were found concurrently with endometrial cancer. However, only
one colorectal cancer was diagnosed concurrently with endome-
trial cancer. Apart from the simultaneous cases, the interval be-
tween the ﬁrst and second tumor was <2 years in four cases, <3
years in one case, and <5 years in one case, and >5 years in three
cases. Among the six patients who had breast cancer, two patients
had taken tamoxifen for 26 months and 16 months, respectively,
before the diagnosis of endometrial cancer. The interval from the
last dose of tamoxifen to the diagnosis of endometrial cancer was
46.1 months and 1 month, respectively. BMI of two patients who
had taken tamoxifen was 26.7 and 21.8 and there was no familial
history of cancers.
The majority of the women in the hereditary predisposition
group presented at Stage I. However, the proportion of patients
who presented at Stage I was not statistically different between the
groupwith a hereditary predisposition and the groupwith sporadic
endometrial cancer (85% and 76%, respectively, p ¼ 0.561). Tumor
grade and histological type were not signiﬁcantly different be-
tween the two groups (p ¼ 0.804 and p ¼ 0.999, respectively).
Lower uterine segment involvement, a factor suggestive of hered-
itary endometrial cancer, was not different between the groupwith
endometrial cancer and a hereditary predisposition and the group
with sporadic endometrial cancer (15% and 11%, p ¼ 0.471).
The median follow-up period was 60 months (range, 1e102
months). There were three cases of recurrence (15%); all patients
Table 1
Clinicopathological characteristics of endometrial cancer with a hereditary component based on synchronous tumors.
Endometrial cancer
(N ¼ 282) N (%)
Sporadic endometrial
cancer (N ¼ 262) N (%)
Endometrial cancer
with a hereditary
component (N ¼ 20) N (%)
p
Mean age (y) 53.2 53.0 55.5 0.791
Age
50 101 (36) 93 (36) 8 (40)
>50 181 (64) 169 (64) 12 (60) 0.428
Menarche (y) 15.6 15.7 14.6 0.168
Parity (N) 2.2 2.2 2.3 0.786
Menopause (y) 51 51 49 0.226
Menopause
Yes 153 (57) 140 (56) 13 (65)
No 117 (43) 110 (44) 7 (35) 0.227
Diabetes
Yes 25 (12) 23 (12) 2 (10)
No 179 (88) 162 (88) 17 (90) 0.149
Body mass index 25.2 25.2 24.7 0.434
Histologic type
Endometrioid 248 (84) 230 (88) 18 (90)
Nonendometrioid 33 (11) 31 (12) 2 (10) 0.999
Grade
G1 126 (45) 119 (50) 7 (37)
G2 88 (30) 80 (33) 8 (42)
G3 45 (15) 41 (17) 4 (21) 0.804
Stage
I 217 (77) 200 (77) 17 (85)
II 17 (6) 17 (6) 0
III 46 (16) 43 (16) 3 (15)
IV 2 (1) 2 (1) 0 0.791
Lower uterine segment involvement
Yes 31 (11) 28 (11) 3 (15)
No 251 (89) 234 (89) 17 (75) 0.471
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clavicular lymph node metastasis. The concurrent tumors of
recurrent patients were breast (n ¼ 1) and colon (n ¼ 2). Two pa-
tients with recurrence had Stage Ia endometrial cancer and another
patient with recurrence had Stage IIIa endometrial cancer. All
recurrent patients were treated with combination chemotherapy.
The 5-year progression-free survival rate and the 5-year overallTable 2
Characteristics of synchronous tumor.
N
Type of cancer
Ovary 10
Breast 6
Colorectal 4
Initially diagnosed cancer type
Ovary 6
Breast 3
Colorectal 11
Interval between ﬁrst and second tumor simultaneous detection 11
<1 y 0
<2 y 4
<3 y 1
<5 y 1
5 y 3
Synchronous ovarian cancer stage
I 7
III 3
Synchronous breast cancer stage
II 2
III 3
Unknown 1
Synchronous colon cancer stage
I 1
III 1
Unknown 2survival rate of the total endometrial cancer patients were 85% and
95%, respectively. The 5-year progression-free survival rate was not
signiﬁcantly different between the endometrial cancer with a he-
reditary predisposition group and the sporadic endometrial cancer
group (86% and 71%, respectively, p ¼ 0.271, Fig. 1). The 5-year
overall survival rate was also not signiﬁcantly different between
the two groups (95% and 95%, respectively, p ¼ 0.659; Fig. 1).
However, among a subgroup of Stage I endometrial cancer patients,
the 5-year progression-free survival and 5-year overall survival
rates were lower in the endometrial cancer with a hereditary
predisposition group compared with the sporadic endometrial
cancer group (73% vs. 93%, p ¼ 0.026 and 94% vs. 98%, p ¼ 0.027,
respectively, Fig. 2). The median follow up of the two groups in
Stage I was 36 months and 64 months, respectively.Discussion
In this study, survival outcome was signiﬁcantly lower in pa-
tients with Stage I endometrial cancer with a hereditary predis-
position. This may indicate a different prognostic role of heredity in
endometrial cancer compared with ovarian cancer [8,14,15].
Increased sensitivity to chemotherapy is one of the explanations
provided for the better survival rate of ovarian cancer patients with
a familial history of ovarian cancer/breast cancer [8]. Unlike ovarian
cancer, most endometrial cancers are diagnosed in the early stages
and adjuvant treatments are restrictively performed [16,17]. The
exact reason for the lower survival outcome in patients with
endometrial cancer with a hereditary predispositionwas difﬁcult to
identify in this study because of the limited number of cases and
study design. Surgical methodology should also be considered as a
part of the survival difference [18], however, because the current
study is not prospective this was not evaluated. Genetic testing was
limited in the current study because of the medical environment
regulated by the HIRA in Korea [19]. Therefore, a larger cohort study
Fig. 2. Overall survival and progression-free survival of Stage I endometrial cancer
between the sporadic and hereditary predisposition groups.
Fig. 1. Overall survival and progression-free survival of patients who have sporadic
endometrial cancer and endometrial cancer with a hereditary predisposition.
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predisposition is needed to conﬁrm this new ﬁnding and to inter-
pret the cause in near future.
Obesity and diabetes are well-known risk factors for endome-
trial carcinoma. We have previously compared the BMI between
the sporadic and hereditary nonpolyposis colorectal cancer
(HNPCC)-related endometrial cancer groups and found that there
was a difference in the proportion. Especially, among the nonobese
patients, the proportion of normal weight was signiﬁcantly higher
in the HNPCC-related group than in the sporadic endometrial
cancer group [20]. In this study, no signiﬁcant difference was
identiﬁed in BMI and diabetes between the hereditary group (ac-
cording to the presence of synchronous malignancy) and the spo-
radic group. Wang et al [21] reported an association of diabetes
with hereditary endometrial cancer; however, the prevalence of
diabetes was not different between those with HNPCC and those
without HNPCC. The results of our study are consistent with those
of Wang and co-workers’ study. This ﬁnding should be more clearly
revealed in a larger population.
Endometrial cancer in the lower uterine segment is one of the
markers of HNPCC [22e24]. The endometrium in the lower uterinesegment is less responsive to hormones [25]. In this study, the
proportion of patients with lower uterine segment involvement
was not statistically different between the two groups. Further
studies are needed to conﬁrm this result.
We recognize that our study has certain limitations. First, with
retrospective data collection in this study, selection bias and other
confounders can be present. Second, we based hereditary predis-
position on the presence of double primary cancer. However, the
diagnosis of double primary cancer was based on pathological re-
ports. Therefore, it is completely reproducible. This is also one of
the strong merits of the study [26]. Third, we did not perform ge-
netic testing to conﬁrm a germline mutation. Even with these
limitations, we investigated the proportion of patients with a he-
reditary predisposition and the prognostic role of hereditary pre-
disposition (based on the presence of synchronous cancer) in
endometrial cancer patients.
In conclusion, we found that approximately 7% of the endo-
metrial cancer patients had other malignancies such as ovarian,
colon, or breast cancer synchronously. In addition, the recurrence
rate and the overall survival rate were not signiﬁcantly different
between the sporadic group and the hereditary predisposition
group. However, among a subgroup of Stage I endometrial cancer
patients, the 5-year progression-free survival and 5-year overall
H.J. Yoo et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 24e2828survival rates were lower in the endometrial cancer with a hered-
itary predisposition group. These results should be further veriﬁed
by future studies using a larger study population.Conﬂicts of interest
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